These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 20542480)

  • 1. Genetic susceptibility to breast cancer.
    Mavaddat N; Antoniou AC; Easton DF; Garcia-Closas M
    Mol Oncol; 2010 Jun; 4(3):174-91. PubMed ID: 20542480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    Wang X; Pankratz VS; Fredericksen Z; Tarrell R; Karaus M; McGuffog L; Pharaoh PD; Ponder BA; Dunning AM; Peock S; Cook M; Oliver C; Frost D; ; Sinilnikova OM; Stoppa-Lyonnet D; Mazoyer S; Houdayer C; ; Hogervorst FB; Hooning MJ; Ligtenberg MJ; ; Spurdle A; Chenevix-Trench G; ; Schmutzler RK; Wappenschmidt B; Engel C; Meindl A; Domchek SM; Nathanson KL; Rebbeck TR; Singer CF; Gschwantler-Kaulich D; Dressler C; Fink A; Szabo CI; Zikan M; Foretova L; Claes K; Thomas G; Hoover RN; Hunter DJ; Chanock SJ; Easton DF; Antoniou AC; Couch FJ
    Hum Mol Genet; 2010 Jul; 19(14):2886-97. PubMed ID: 20418484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA).
    Chenevix-Trench G; Milne RL; Antoniou AC; Couch FJ; Easton DF; Goldgar DE;
    Breast Cancer Res; 2007; 9(2):104. PubMed ID: 17466083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers.
    Milne RL; Antoniou AC
    Ann Oncol; 2011 Jan; 22 Suppl 1():i11-7. PubMed ID: 21285145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.
    Mulligan AM; Couch FJ; Barrowdale D; Domchek SM; Eccles D; Nevanlinna H; Ramus SJ; Robson M; Sherman M; Spurdle AB; Wappenschmidt B; Lee A; McGuffog L; Healey S; Sinilnikova OM; Janavicius R; Hansen Tv; Nielsen FC; Ejlertsen B; Osorio A; Muñoz-Repeto I; Durán M; Godino J; Pertesi M; Benítez J; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Cattaneo E; Bonanni B; Viel A; Pasini B; Papi L; Ottini L; Savarese A; Bernard L; Radice P; Hamann U; Verheus M; Meijers-Heijboer HE; Wijnen J; Gómez García EB; Nelen MR; Kets CM; Seynaeve C; Tilanus-Linthorst MM; van der Luijt RB; van Os T; Rookus M; Frost D; Jones JL; Evans DG; Lalloo F; Eeles R; Izatt L; Adlard J; Davidson R; Cook J; Donaldson A; Dorkins H; Gregory H; Eason J; Houghton C; Barwell J; Side LE; McCann E; Murray A; Peock S; Godwin AK; Schmutzler RK; Rhiem K; Engel C; Meindl A; Ruehl I; Arnold N; Niederacher D; Sutter C; Deissler H; Gadzicki D; Kast K; Preisler-Adams S; Varon-Mateeva R; Schoenbuchner I; Fiebig B; Heinritz W; Schäfer D; Gevensleben H; Caux-Moncoutier V; Fassy-Colcombet M; Cornelis F; Mazoyer S; Léoné M; Boutry-Kryza N; Hardouin A; Berthet P; Muller D; Fricker JP; Mortemousque I; Pujol P; Coupier I; Lebrun M; Kientz C; Longy M; Sevenet N; Stoppa-Lyonnet D; Isaacs C; Caldes T; de la Hoya M; Heikkinen T; Aittomäki K; Blanco I; Lazaro C; Barkardottir RB; Soucy P; Dumont M; Simard J; Montagna M; Tognazzo S; D'Andrea E; Fox S; Yan M; Rebbeck T; Olopade O; Weitzel JN; Lynch HT; Ganz PA; Tomlinson GE; Wang X; Fredericksen Z; Pankratz VS; Lindor NM; Szabo C; Offit K; Sakr R; Gaudet M; Bhatia J; Kauff N; Singer CF; Tea MK; Gschwantler-Kaulich D; Fink-Retter A; Mai PL; Greene MH; Imyanitov E; O'Malley FP; Ozcelik H; Glendon G; Toland AE; Gerdes AM; Thomassen M; Kruse TA; Jensen UB; Skytte AB; Caligo MA; Soller M; Henriksson K; Wachenfeldt vA; Arver B; Stenmark-Askmalm M; Karlsson P; Ding YC; Neuhausen SL; Beattie M; Pharoah PD; Moysich KB; Nathanson KL; Karlan BY; Gross J; John EM; Daly MB; Buys SM; Southey MC; Hopper JL; Terry MB; Chung W; Miron AF; Goldgar D; Chenevix-Trench G; Easton DF; Andrulis IL; Antoniou AC; ; ; ; ; ; ; ;
    Breast Cancer Res; 2011; 13(6):R110. PubMed ID: 22053997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unravelling modifiers of breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: update on genetic modifiers.
    Barnes DR; Antoniou AC
    J Intern Med; 2012 Apr; 271(4):331-43. PubMed ID: 22443199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
    Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    Hughes DJ
    Fam Cancer; 2008; 7(3):233-44. PubMed ID: 18283561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "Other" breast cancer susceptibility genes: searching for more holy grail.
    Nathanson KL; Weber BL
    Hum Mol Genet; 2001 Apr; 10(7):715-20. PubMed ID: 11257104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
    Kadouri L; Easton DF; Edwards S; Hubert A; Kote-Jarai Z; Glaser B; Durocher F; Abeliovich D; Peretz T; Eeles RA
    Br J Cancer; 2001 Jul; 85(1):36-40. PubMed ID: 11437399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs.
    Li N; Rowley SM; Thompson ER; McInerny S; Devereux L; Amarasinghe KC; Zethoven M; Lupat R; Goode D; Li J; Trainer AH; Gorringe KL; James PA; Campbell IG
    Breast Cancer Res; 2018 Jan; 20(1):3. PubMed ID: 29316957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of BRCA1 and BRCA2 mutations in a large United States sample.
    Chen S; Iversen ES; Friebel T; Finkelstein D; Weber BL; Eisen A; Peterson LE; Schildkraut JM; Isaacs C; Peshkin BN; Corio C; Leondaridis L; Tomlinson G; Dutson D; Kerber R; Amos CI; Strong LC; Berry DA; Euhus DM; Parmigiani G
    J Clin Oncol; 2006 Feb; 24(6):863-71. PubMed ID: 16484695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group.
    Anglian Breast Cancer Study Group
    Br J Cancer; 2000 Nov; 83(10):1301-8. PubMed ID: 11044354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Common genetic variants contribute to incomplete penetrance: evidence from cancer-free BRCA1 mutation carriers.
    Downs B; Sherman S; Cui J; Kim YC; Snyder C; Christensen M; Luo J; Lynch H; Wang SM
    Eur J Cancer; 2019 Jan; 107():68-78. PubMed ID: 30551077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Common low-penetrance risk variants associated with breast cancer in Polish women.
    Ledwoń JK; Hennig EE; Maryan N; Goryca K; Nowakowska D; Niwińska A; Ostrowski J
    BMC Cancer; 2013 Oct; 13():510. PubMed ID: 24171766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases.
    Malone KE; Daling JR; Neal C; Suter NM; O'Brien C; Cushing-Haugen K; Jonasdottir TJ; Thompson JD; Ostrander EA
    Cancer; 2000 Mar; 88(6):1393-402. PubMed ID: 10717622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.